Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 28,805 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Medication Clear all
Completed Not applicable Interventional

Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1

NCT02944032
View directory record Official record
Conditions
Neurofibromatosis Type 1
Interventions
CogmedRM, Mobymax
Other
Lead sponsor
Kristina Hardy
Other
Eligibility
8 Years to 16 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 24, 2026, 10:01 PM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

NCT04930887
View directory record Official record
Conditions
Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal Hemicrania
Interventions
Exparel (Bupivacaine Liposome), Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 1Phase 2 Interventional

Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs

NCT00062816
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
ISIS 14803, peginterferon alfa, ribavirin
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 24, 2026, 10:01 PM EDT
Withdrawn Phase 2 Interventional

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

NCT03035630
View directory record Official record
Conditions
Clear-cell Renal Cell Carcinoma, RCC, Kidney Cancer, Clear-cell Kidney Carcinoma
Interventions
Avelumab, Sunitinib
Drug
Lead sponsor
Guru Sonpavde
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 24, 2026, 10:01 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

NCT03580928
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
Venetoclax, Obinutuzumab, Acalabrutinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Stamford, Connecticut • Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 3 Interventional Results available

This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment

NCT00150800
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB PHARMA Inc. (US)
Industry
Eligibility
16 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 24, 2026, 10:01 PM EDT
Active, not recruiting Not applicable Interventional

CBT-I to Improve Functional Outcomes in Veterans With Psychosis

NCT04646200
View directory record Official record
Conditions
Insomnia, Psychosis
Interventions
Cognitive Behavioral Therapy-Insomnia, Health and Wellness
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 24, 2026, 10:01 PM EDT
Recruiting Phase 4 Interventional

Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study

NCT04191681
View directory record Official record
Conditions
Stage D Heart Failure
Interventions
Sacubitril-Valsartan, Usual care (standard-of-care) arm
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Healthy Heart Habits

NCT04158219
View directory record Official record
Conditions
Acute Coronary Syndrome, Depression
Interventions
Behavioral activation for health and depression (BA-HD)
Behavioral
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

NCT01667536
View directory record Official record
Conditions
Prostate Cancer
Interventions
Drug: 99mTc-MIP-1404
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Duarte, California • Rochester, Minnesota • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 24, 2026, 10:01 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

NCT06827236
View directory record Official record
Conditions
Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
Interventions
BNT323, BNT327
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
28
States / cities
Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Circadian Rhythms of Aqueous Humor Dynamics in Humans

NCT00572936
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Dorzolamide, Timolol
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 1 Interventional

Acupuncture to Reduce Symptoms of Advanced Colorectal Cancer

NCT00034034
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Acupuncture
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2007 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

NCT00879034
View directory record Official record
Conditions
Progeria, Hutchinson-Gilford Syndrome
Interventions
Lonafarnib, Zoledronic Acid, Pravastatin
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 3 Interventional Results available

Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure

NCT01499134
View directory record Official record
Conditions
Peripheral Artery Disease, Hypertension
Interventions
nebivolol, Metoprolol succinate
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Not applicable Interventional Results available

TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation

NCT03354663
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
TactiCath SE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
Little Rock, Arkansas • La Jolla, California • Redwood City, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence of RYTHMOL SR® Manufactured at Two Different Sites

NCT01956487
View directory record Official record
Conditions
Arrhythmia, Cardiac
Interventions
Propafenone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 24, 2026, 10:01 PM EDT
Terminated Phase 3 Interventional

Helping Children With Trauma

NCT02737488
View directory record Official record
Conditions
Trauma, Post-Traumatic Stress Disorder
Interventions
Trauma Systems Therapy (TST), Treatment as Usual (TAU)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
7 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Not applicable Interventional

Safely Disposing of Surplus Prescription Opioids

NCT03855241
View directory record Official record
Conditions
Opioid Use
Interventions
Informational Sheet, DisposeRx Drug Disposal kit
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 3 Interventional

Evaluating a Telemedicine Smoking Cessation Program in Rural Primary Care Practices

NCT00843505
View directory record Official record
Conditions
Smoking
Interventions
Telemedicine Smoking Cessation Program, Telephone Quitline Smoking Cessation Program
Behavioral
Lead sponsor
Kimber Richter, PhD, MPH, MA
Other
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

A Study of N-Acetyl Cysteine in Children With Autism

NCT00627705
View directory record Official record
Conditions
Autistic Disorder
Interventions
N-Acetyl Cysteine, Placebo - sugar pill
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 12 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 24, 2026, 10:01 PM EDT
Not listed Phase 1 Interventional

Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)

NCT04629105
View directory record Official record
Conditions
ARDS, Human, Covid19
Interventions
Longeveron Mesenchymal Stem Cells (LMSCs), Placebo
Biological · Other
Lead sponsor
Longeveron Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

Subacromial Corticosteroid Injection for Hemiplegic Shoulder Pain

NCT00597766
View directory record Official record
Conditions
Shoulder Pain
Interventions
Lidocaine, Triamcinolone + Lidocaine
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 24, 2026, 10:01 PM EDT
Completed Phase 3 Interventional Results available

Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

NCT02475629
View directory record Official record
Conditions
HIV
Interventions
ibalizumab, Optimized Background Regimen (OBR)
Biological · Drug
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
27
States / cities
Long Beach, California • Los Angeles, California • Palm Springs, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 24, 2026, 10:01 PM EDT